Plasma and Cerebrospinal Fluid Pharmacokinetics of Moxifloxacin in a Patient with Tuberculous Meningitis-Reference-Cited by-同舟云学术

Plasma and Cerebrospinal Fluid Pharmacokinetics of Moxifloxacin in a Patient with Tuberculous Meningitis

Published:2008-06 Issue:6 Volume:52 Page:2293-2295
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Alffenaar J. W. C.¹,de Vries P. M.²,Luijckx G. J.²,van Soolingen D.³,van der Werf T. S.⁴,van Altena R.⁵

Affiliation:

1. Department of Hospital and Clinical Pharmacy  University Medical Center Groningen  University of Groningen  P.O. Box 30.001  9700 RB Groningen, The Netherlands

2. Department of Neurology  University Medical Center Groningen  University of Groningen  Groningen, The Netherlands

3. National Mycobacteria Reference Laboratory  National Institute of Public Health and the Environment  Bilthoven, The Netherlands

4. Departments of Internal Medicine and of Pulmonary Diseases & Tuberculosis  University Medical Center Groningen  University of Groningen  Groningen, The Netherlands

5. Tuberculosis Centre Beatrixoord  University Medical Center Groningen  University of Groningen  Haren, The Netherlands

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01637-07

Reference14 articles.

1. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

2. Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis

3. Codecasa, L. R., G. Ferrara, M. Ferrarese, M. A. Morandi, V. Penati, C. Lacchini, P. Vaccarino, and G. B. Migliori. 2006. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir. Med.100:1566-1572.

4. Nijland, H. M. J., R. Ruslami, A. J. Suroto, D. M. Burger, B. Alisjahbana, R. van Crevel, and R. E. Aarnoutse. 2007. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin. Infect. Dis.45:1001-1007.

5. Evaluation of Moxifloxacin, a New 8-Methoxyquinolone, for Treatment of Meningitis Caused by a PenicillinResistant Pneumococcus in Rabbits

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults;Antibiotics;2022-12-19

2. Antifungal drugs: An updated review of central nervous system pharmacokinetics;Mycoses;2020-09-04

3. Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment;Journal of Central Nervous System Disease;2019-01

4. Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis;Pharmacogenomics;2018-01

5. Pharmacokinetics of intravenous moxifloxacin in the cerebrospinal fluid of a patient with central nervous system shunt infection;Diagnostic Microbiology and Infectious Disease;2016-03